1. Home
  2. AVDL vs BELFA Comparison

AVDL vs BELFA Comparison

Compare AVDL & BELFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • BELFA
  • Stock Information
  • Founded
  • AVDL 2015
  • BELFA 1949
  • Country
  • AVDL Ireland
  • BELFA United States
  • Employees
  • AVDL N/A
  • BELFA 5370
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • BELFA
  • Sector
  • AVDL Health Care
  • BELFA
  • Exchange
  • AVDL Nasdaq
  • BELFA Nasdaq
  • Market Cap
  • AVDL 1.4B
  • BELFA 1.6B
  • IPO Year
  • AVDL 1996
  • BELFA N/A
  • Fundamental
  • Price
  • AVDL $15.66
  • BELFA $122.61
  • Analyst Decision
  • AVDL Strong Buy
  • BELFA
  • Analyst Count
  • AVDL 8
  • BELFA 0
  • Target Price
  • AVDL $20.88
  • BELFA N/A
  • AVG Volume (30 Days)
  • AVDL 1.5M
  • BELFA 9.5K
  • Earning Date
  • AVDL 11-11-2025
  • BELFA 10-22-2025
  • Dividend Yield
  • AVDL N/A
  • BELFA 0.19%
  • EPS Growth
  • AVDL N/A
  • BELFA N/A
  • EPS
  • AVDL N/A
  • BELFA 4.05
  • Revenue
  • AVDL $221,075,000.00
  • BELFA $594,034,000.00
  • Revenue This Year
  • AVDL $64.56
  • BELFA $25.48
  • Revenue Next Year
  • AVDL $30.60
  • BELFA $5.57
  • P/E Ratio
  • AVDL N/A
  • BELFA $30.53
  • Revenue Growth
  • AVDL 132.35
  • BELFA 6.08
  • 52 Week Low
  • AVDL $6.38
  • BELFA $53.95
  • 52 Week High
  • AVDL $16.66
  • BELFA $126.80
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 65.57
  • BELFA 59.65
  • Support Level
  • AVDL $14.78
  • BELFA $116.00
  • Resistance Level
  • AVDL $16.04
  • BELFA $126.80
  • Average True Range (ATR)
  • AVDL 0.57
  • BELFA 2.93
  • MACD
  • AVDL -0.11
  • BELFA 0.09
  • Stochastic Oscillator
  • AVDL 79.23
  • BELFA 74.02

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About BELFA Bel Fuse Inc.

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

Share on Social Networks: